Skip to main content
Terug
ACLX logo

Arcellx, Inc.

Datakwaliteit: 100%
Overbought
ACLX
NASDAQ Healthcare Biotechnology
€ 114,69
▲ € 0,09 (0,08%)
Marktkapitalisatie: 6,71B
Dagbereik
€ 114,40 € 114,70
52-Weeksbereik
€ 47,86 € 114,91
Volume
1.377.509
50D / 200D Gem.
€ 86,59 / € 77,34
Vorige Slotkoers
€ 114,60

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -29,3 0,4
P/B 16,7 2,9
ROE % -53,4 3,9
Net Margin % -1027,3 3,8
Rev Growth 5Y % 10,0
D/E 0,2 0,2

Koersdoel Analisten

Hold
€ 110,42 -3.7%
Low: € 82,00 High: € 120,00
Forward WPA
-€ 3,52
Omzet Sch.
87 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 3,87
€ 1,35 – € 8,12
740 M 4
FY2028 € 0,33
-€ 0,48 – € 1,22
460 M 10
FY2027 -€ 1,61
-€ 5,47 – € 1,86
270 M 10

Belangrijkste Punten

Debt/Equity of 0,24 — conservative balance sheet
Negative free cash flow of -212,59M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-79,35%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-53,42%
ROIC-38,07%
Net Margin-1027,25%
Op. Margin-1135,61%

Veiligheid

Debt / Equity
0,24
Current Ratio4,44
Interest Coverage-10,45

Waardering

P/E Ratio
-29,30
P/B Ratio16,67
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -79,35% Revenue Growth (3Y) -55,05%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 22,29M Net Income (TTM) -228,93M
ROE -53,42% ROA -37,90%
Gross Margin 70,03% Operating Margin -1135,61%
Net Margin -1027,25% Free Cash Flow (TTM) -212,59M
ROIC -38,07% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,24 Current Ratio 4,44
Interest Coverage -10,45 Dividend Yield 0,00%
Valuation
P/E Ratio -29,30 P/B Ratio 16,67
P/S Ratio 300,95 PEG Ratio -0,15
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 6,71B Enterprise Value 6,72B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 22,29M 107,94M 110,32M 0,0 0,0
Net Income -228,93M -107,35M -70,69M -188,68M -64,97M
EPS (Diluted) -4,07 -2,00 -1,47 -4,28 -1,94
Gross Profit 15,61M 102,75M 110,32M -2,22M 0,0
Operating Income -253,08M -137,57M -89,88M -191,26M -65,02M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 603,99M 711,33M 825,13M 313,82M 128,78M
Total Liabilities 201,64M 256,54M 339,75M 108,86M 250,30M
Shareholders' Equity 402,35M 454,79M 485,38M 204,95M -121,52M
Total Debt 96,26M 54,08M 97,63M 88,13M 0,0
Cash & Equivalents 80,26M 105,68M 394,58M 64,18M 30,83M
Current Assets 462,18M 599,31M 716,36M 266,86M 112,81M
Current Liabilities 104,20M 125,41M 118,24M 56,69M 14,85M